#United States #Franklin Lakes #Becton #Dickinson #Menziuso

Peter Menziuso Takes the Helm at BD Interventional

BD (Becton, Dickinson and Company), a global leader in medical technology, has recently made headlines with the appointment of Peter Menziuso as Executive Vice President and President of BD Interventional, effective June 1. This strategic move is set to enhance BD Interventional’s market position and push forward its commitment to improving healthcare systems worldwide.

Peter Menziuso brings over three decades of extensive experience within the healthcare industry, marked by a proven track record of driving growth through disciplined and strategic execution. Previously, he held the position of Company Group Chairman at Johnson & Johnson Vision, where he skillfully managed a $5 billion global business encompassing areas like commercial operations, research and development, supply chain management, quality assurance, finance, and medical affairs. Menziuso’s expertise will be invaluable as he transitions into this new role, bringing his strategic insight and operational expertise to BD.

Throughout his illustrious career, Menziuso has garnered recognition for his ability to fortify market leadership, assemble high-performing teams, and adeptly translate strategies into sustained business performance through operational excellence. His extensive global leadership experience, coupled with a relentless focus on customer needs, uniquely positions him to accelerate the execution of BD Interventional’s initiatives and cultivate sustained growth.

In the words of Tom Polen, CEO and Chairman of BD, “BD Interventional has a strong track record of performance, and Peter is the right leader to build on that momentum and continue delivering results.” Polen emphasized that Menziuso's strategic leadership and operational discipline make him a perfect fit for the company’s vision and ambitious goals.

BD Interventional has continued to make significant advancements in medical technology, dedicated to enhancing patient care and clinical outcomes. The firm is recognized for delivering innovative medical products and solutions that meet the complex demands of healthcare institutions and their surrounding environments. Menziuso’s assignment to the position is expected to further bolster BD’s efforts in this area.

BD stands among the largest pure-play medical technology companies globally, with a purpose of advancing world health and enhancing patient outcomes. The company achieves this through innovation in essential medical technologies, connected care, biopharma systems, and interventional solutions. Operating with a worldwide workforce of over 60,000, BD supplies billions of products annually, impacting healthcare positively across the globe.

As Menziuso steps into his new role, industry observers remain optimistic about the future trajectory of BD Interventional under his leadership. The combination of his strategic insight and operational expertise is anticipated to yield continued growth and innovation, ensuring heightened performance in the healthcare technology sector. BD Interventional’s commitment to transforming patient care through its advanced technologies remains paramount, and under Menziuso’s guidance, the division aims to navigate upcoming challenges and opportunities effectively.

In conclusion, Peter Menziuso’s ascendance to the presidency of BD Interventional signifies an exciting era for both the company and the global healthcare landscape. With a focused approach on operational excellence and customer-centric initiatives, the future appears bright for BD Interventional as it continues to drive healthcare innovations forward.

For further inquiries or information on BD Interventional, please connect with the company through its official channels, including their LinkedIn page and other social media platforms.